Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD (original) (raw)
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209 ArticlePubMed Google Scholar
Liu CJ, Chen PJ. Elimination of hepatitis B in highly endemic settings: lessons learned in Taiwan and challenges ahead. Viruses. 2020;12:815 ArticleCASPubMedPubMed Central Google Scholar
Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16:57–73 ArticlePubMed Google Scholar
Vaz K, Clayton-Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int. 2023;17:1082–1097 ArticlePubMed Google Scholar
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–873 ArticlePubMed Google Scholar
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84 ArticlePubMed Google Scholar
Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: honoring the winners of the nobel prize in physiology or medicine 2020. Kaohsiung J Med Sci. 2021;37:7–11 ArticlePubMed Google Scholar
Younossi ZM, Henry L, Janus PO, Tanaka A, Eguchi Y, Mizokami M, et al. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther. 2019;49:644–653 ArticlePubMed Google Scholar
Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394(10200):781–792 ArticlePubMed Google Scholar
Seto WK. Chronic hepatitis B and metabolic risk factors: a call for rigorous longitudinal studies. World J Gastroentrol. 2019;25:282–286 Article Google Scholar
Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, et al. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2020;119:1476–1482 ArticlePubMed Google Scholar
Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, et al. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease. Gut Liver. 2021;15:451–458 ArticlePubMedPubMed Central Google Scholar
Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin Gastroenterol Hepatol. 2020;18:995–997 ArticlePubMed Google Scholar
Wong VS, Wong GH, Chu WW, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540 ArticlePubMed Google Scholar
Sakhuja P, Kumar A, Hissar S, et al. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol. 2011;54:454–459 ArticlePubMed Google Scholar
Wang CC, Cheng PN, Kao JH. Systemic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020;51:216–230 ArticlePubMed Google Scholar
Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361–1367 ArticlePubMed Google Scholar
Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65:828–835 ArticleCASPubMed Google Scholar
Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B–a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883–893 ArticleCASPubMed Google Scholar
Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology. 2017;153:1006–1017 ArticlePubMed Google Scholar
Patmore LA, Katwaroe WK, van der Spek D, et al. Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2023;21:3089–3096 ArticleCASPubMed Google Scholar
Huang SC, Su TH, Tseng TC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17:1139–1149 ArticlePubMed Google Scholar
Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, et al. Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion. Clin Gastroenterol Hepatol. 2023:S1542–3565(23)00842-X.
Ceylan B, Arslan F, Batırel A, Fincancı M, Yardımcı C, Fersan E, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol. 2016;27:42–46 ArticlePubMed Google Scholar
Yu JH, Lee JW. How does hepatic steatosis affect the outcome of patients with chronic hepatitis B? Clin Mol Hepatol. 2019;25:280–282 ArticlePubMedPubMed Central Google Scholar
Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44:1071–1079 ArticleCASPubMed Google Scholar
Zhang Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1100–1109 Article Google Scholar
Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12:438–446 ArticlePubMed Google Scholar
Liu Q, Mu M, Chen H, Zhang G, Yang Y, Chu Y, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem. 2022;477:2481–2491 ArticleCASPubMed Google Scholar
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016;44:877–889 ArticleCASPubMedPubMed Central Google Scholar
Boursier J, de Ledinghen V, Leroy V, Anty R, Francque S, Salmon D, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017;66:1158–1165 ArticlePubMed Google Scholar
Xu L, Lu W, Li P, Shen F, Mi YQ, Fan JG. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. Dig Liver Dis. 2017;49:910–917 ArticlePubMed Google Scholar
Liang J, Liu F, Wang F, Han T, Jing L, Ma Z, et al. A noninvasive score model for prediction of NASH in patients with chronic hepatitis B and nonalcoholic fatty liver disease. BioMed Res Int. 2017;2017:8793278 ArticlePubMedPubMed Central Google Scholar
Dong DR, Hao MN, Li C, Peng Z, Liu X, Wang GP, et al. Acoustic radiation force impulse elastography, FibroScan®, Forns’ index and their combination in the assessment of liver fibrosis in patients with chronic hepatitis B, and the impact of inflammatory activity and steatosis on these diagnostic methods. Mol Med Rep. 2015;11:4174–4182 ArticleCASPubMedPubMed Central Google Scholar
Cho Y, Cho EJ, Yoo JJ, et al. Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study. Cancers (Basel). 2021;13:1599 ArticleCASPubMed Google Scholar
Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32:667–676 ArticleCASPubMed Google Scholar
Zhou R, Yang L, Zhang B, Gu Y, Kong T, Zhang W, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: a systematic review and meta-analysis. J Viral hepat. 2023;30:793–802 ArticleCASPubMed Google Scholar
Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, et al. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023;29:705–720 ArticlePubMedPubMed Central Google Scholar
Mak LY, Hui RW, Lee CH, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. Hepatology. 2023;77:606–618 PubMed Google Scholar
Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237–1243 ArticlePubMed Google Scholar
Huang CF, Dai CY, Yeh ML, Huang CI, Lee HC, Lai WT, et al. Cure or curd: modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36:920–928 ArticleCASPubMed Google Scholar
Attia D, Abdel Alem S, El-Akel W, Abdel-Razek W, Eslam M, Fouad Y, et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Aliment Pharmacol Ther. 2022;56:1581–1590 ArticleCASPubMed Google Scholar
Cheng KL, Wang SW, Cheng YM, Hsieh TH, Wang CC, Kao JH. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease. J Formos Med Assoc. 2024;123:36–44 ArticleCASPubMed Google Scholar
Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586–597 ArticleCASPubMed Google Scholar
Huang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol. 2015;62:512–518 ArticleCASPubMed Google Scholar
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20 ArticlePubMed Google Scholar
Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705–709 ArticlePubMed Google Scholar
Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol. 2005;40:329–336 ArticleCASPubMed Google Scholar
Lu MY, Huang JF, Liao YC, Bai RK, Trieu RB, Chuang WL, et al. Mitochondrial polymorphism 12361A>G is associated with nonalcoholic fatty liver disease. Transl Res. 2012;159:58–59 ArticleCASPubMed Google Scholar
Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, et al. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep. 2016;6:22995 ArticleCASPubMedPubMed Central Google Scholar
Lu MY, Yeh ML, Huang CI, Wang SC, Tsai YS, Tsai PC, et al. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World J Gastroenterol. 2022;28:140–153 ArticleCASPubMedPubMed Central Google Scholar
Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc. 2020;119:1019–1040 ArticlePubMed Google Scholar
Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605–1616 ArticlePubMed Google Scholar
Wong RJ, Chou C, Sinha SR, Kamal A, Ahmed A. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health. 2014;39:437–445 ArticlePubMed Google Scholar
Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Lee MH, et al. Community-centered disease severity assessment of metabolic dysfunction-associated fatty liver disease. J Clin Transl Hepatol. 2023;11:1061–1068 PubMedPubMed Central Google Scholar
Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59:1279–1287 ArticleCASPubMed Google Scholar
Oliveira C, Fournier C, Descamps V, Morel V, Scipione CA, Romagnuolo R, et al. Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. Hepatology. 2017;65:1851–1864 ArticleCASPubMed Google Scholar
Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999;96:12766–12771 ArticleCASPubMedPubMed Central Google Scholar
Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat. 2006;13:73–80 ArticleCASPubMed Google Scholar
Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34:428–434 ArticleCASPubMed Google Scholar
Shih CI, Wu KT, Hsieh MH, Yang JF, Chen YY, Tsai WL, et al. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study. Hepatol Int. 2023. https://doi.org/10.1007/s12072-023-10576-z ArticlePubMed Google Scholar
Yeh ML, Yu ML. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: updates of nomenclature and impact on clinical trials. Clin Mol Hepatol. 2023;29:969–972 ArticlePubMed Google Scholar
Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712–718 ArticleCASPubMed Google Scholar
Chen CH, Huang JF, Huang CF, Yeh ML, Yang JF, Hsieh MY, et al. Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatol Int. 2013;7:162–170 ArticlePubMed Google Scholar
Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496–502 ArticleCASPubMed Google Scholar
Rout G, Nayak B, Patel AH, Gunjan D, Singh V, Kedia S, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol. 2019;9:207–214 ArticlePubMed Google Scholar
Trifan A, Stratina E, Rotaru A, Stafie R, Zenovia S, Nastasa R, et al. Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis c infection treated with direct-acting antivirals therapy who achieved sustained virological response. Diagnostics (Basel). 2022;12:702 ArticleCASPubMed Google Scholar
Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, et al. Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight. Hepatol Res. 2023;53:595–606 ArticleCASPubMed Google Scholar
Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, et al. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis. 2021;53:1301–1307 ArticleCASPubMed Google Scholar
Huang JF, Huang CF, Yeh ML, Dai CY, Hsieh MH, Yang JF, et al. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. Kaohsiung J Med Sci. 2017;33:567–571 ArticlePubMed Google Scholar
Adinolfi LE, Nevola R, Guerrera B, D’Alterio G, Marrone A, Giordano M, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33:1379–1382 ArticleCASPubMed Google Scholar
Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2012;61:128–134 ArticleCASPubMed Google Scholar
Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE. 2018;13: e0209615 ArticleCASPubMedPubMed Central Google Scholar
Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, et al. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int. 2018;38:1064–1073 ArticleCASPubMed Google Scholar
Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, et al. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: a multicenter study. Hepatol Res. 2023. https://doi.org/10.1111/hepr.13993 ArticlePubMed Google Scholar
Pelusi S, Bianco C, Colombo M, Cologni G, Del Poggio P, Pugliese N, et al. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals. Liver Int. 2023;43:1593–1603 ArticleCASPubMed Google Scholar
Degasperi E, Galmozzi S, Pelusi R, D’Ambrosio R, Soffredini, Borghi M, et al. Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs. Hepatology. 2020;72:1912–1923 ArticleCASPubMed Google Scholar
Fouad Y, Lazarus JV, Negro F, Peck-Radosavljevic M, Sarin SK, Ferenci P, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021;53:1080–1089 ArticlePubMed Google Scholar
Hirakawa M, Arase Y, Amakawa K, Ohmoto-Sekine Y, Ishihara M, Shiba M, et al. Relationship between alcohol intake and risk factors for metabolic syndrome in men. Intern Med. 2015;54(17):2139–2145 ArticleCASPubMed Google Scholar
Kim SK, Hong SH, Chung JH, Cho KB. Association between alcohol consumption and metabolic syndrome in a community-based cohort of Korean adults. Med Sci Monit. 2017;23:2104–2110 ArticleCASPubMedPubMed Central Google Scholar
Åberg F, Byrne CD, Pirola CJ, Männistö V, Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J Hepatol. 2023;78:191–206 ArticlePubMed Google Scholar
Sookoian S, Castaño GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut. 2014;63:530–532 ArticlePubMed Google Scholar
Choi JH, Sohn W, Cho YK. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26:662–669 ArticlePubMedPubMed Central Google Scholar
Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, et al. Type and pattern of alcohol consumption is associated with liver fibrosis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2018;113:1484–1493 ArticlePubMed Google Scholar
Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71:835–848 ArticlePubMed Google Scholar
GBD 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global burden of disease study 2020. Lancet. 2022;400:185–235 Article Google Scholar
Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69:64–75 ArticleCASPubMed Google Scholar
Díaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20:764–783 ArticlePubMed Google Scholar
Romeo S, Sanyal A, Valenti L. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab. 2020;31:35–45 ArticleCASPubMed Google Scholar
Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21–23 ArticleCASPubMed Google Scholar
Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty liver disease caused by high-alcohol-producing Klebsiellapneumoniae. Cell Metab. 2019;30:675-688.e7 ArticleCASPubMed Google Scholar
Gan L, Feng Y, Du B, Fu H, Tian Z, Xue G, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun. 2023;14:3215 ArticleCASPubMedPubMed Central Google Scholar
Hahn JA, Fatch R, Barnett NP, Marcus GM. Phosphatidylethanol vs transdermal alcohol monitoring for detecting alcohol consumption among adults. JAMA Netw Open. 2023;6: e2333182 ArticlePubMedPubMed Central Google Scholar
Åberg F, Luukkonen PK, But A, Salomaa V, Britton A, Petersen KM, et al. Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score. J Hepatol. 2022;77:302–311 ArticlePubMed Google Scholar
Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919 ArticlePubMed Google Scholar
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835 ArticlePubMed Google Scholar
Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2021;74:1188–1199 ArticleCASPubMed Google Scholar